Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Practical information

When do the meetings take place?
CRTH 2025 timeline is as follows:

Workshop 1: Tuesday, February 4 – Saturday, February 8, 2025
EHA2025 Congress: Thursday, June 12 – Sunday, June 15, 2025
> CRTH Congress session date TBC.

Read more

2013 & before

2013
EHA-SWG Scientific Meeting on Thrombocytopenia and Disorders of Platelet Function
September 27-29, 2013 | Lisbon, Portugal

EHA-ROHS-RSH Tutorial on Bone Marrow Transplantation
July 5-7, 2013 | Saint Petersburg, Russia

EHA Tutorial on Lymphoma
May 24-26, 2013 | Cape Town, South Africa

EHA-TSH Tutorial on Chronic Myeloproliferative…

Read more

Report "Haematology and the next European Decade"

EHA and the European Cancer Patient Coalition co-hosted a meeting at the European Parliament in Brussels on August 30-31, 2011. The two-day conference was attended by doctors, researchers, parliamentarians, patient advocates and Commission officials.

Read more